trending Market Intelligence /marketintelligence/en/news-insights/trending/63mC4yLcG8fThLFw5WxwGQ2 content esgSubNav
In This List

SIGA Technologies seeks US FDA approval for smallpox treatment

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


SIGA Technologies seeks US FDA approval for smallpox treatment

SIGA Technologies Inc. submitted a new drug application to the U.S. Food and Drug Administration for its smallpox treatment Tpoxx.

Tpoxx was developed to treat smallpox, as well as other orthopoxvirus infections. There is no cure or treatment approved for smallpox.

SIGA has requested an expedited review of its application. The advanced development of Tpoxx is funded by the U.S. government's Biomedical Advanced Research and Development Authority.

The drug is administered in oral form and was developed under the U.S. FDA's animal rule in which efficacy endpoints are determined in animal studies, and human clinical studies are conducted to determine the safety and confirm dosing.

SIGA expects a response from the U.S. FDA in February 2018.